Most recently, allogeneic CD19 CAR-NK cells have shown high efficacy and minimal toxicity in R/R chronic lymphocytic leukemia and B cell lymphoma [162]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.